Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas |
| |
Authors: | Yoshifumi Saisho Paul E. Harris Alexandra E. Butler Ryan Galasso Tatyana Gurlo Robert A. Rizza Peter C. Butler |
| |
Affiliation: | (1) Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, 900 Weyburn Place #A, Los Angeles, CA 90024-2852, USA;(2) Department of Medicine, Columbia University Medical Center, Black Building 20th floor, 650W 168th Street, New York, NY 10032, USA;(3) Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA |
| |
Abstract: | Vesicular monoamine transporter 2 (VMAT2) is expressed in pancreatic beta cells and has recently been proposed as a target for measurement of beta cell mass in vivo. We questioned, (1) What proportion of beta cells express VMAT2? (2) Is VMAT2 expressed by other pancreatic endocrine or non-endocrine cells? (3) Is the relationship between VMAT2 and insulin expression disturbed in type 1 (T1DM) or type 2 diabetes (T2DM)? Human pancreas (7 non-diabetics, 5 T2DM, 10 T1DM) was immunostained for insulin, VMAT2 and other pancreatic hormones. Most beta cells expressed VMAT2. VMAT2 expression was not changed by the presence of diabetes. In tail of pancreas VMAT2 immunostaining closely correlated with insulin staining. However, VMAT2 was also expressed in some pancreatic polypeptide (PP) cells. Although VMAT2 was not excluded as a target for beta cell mass measurement, expression of VMAT2 in PP cells predicts residual VMAT2 expression in human pancreas even in the absence of beta cells. |
| |
Keywords: | Beta cell mass Vesicular monoamine transporter Type 1 diabetes Type 2 diabetes Insulin Pancreatic polypeptide |
本文献已被 PubMed SpringerLink 等数据库收录! |
|